We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Membrane-binding Protein Regulates Cell Motility by Sensing Membrane Tension

By LabMedica International staff writers
Posted on 17 May 2015
A team of Japanese cell biologists has found that the interaction between the degree of plasma membrane tension and a plasma membrane-bending protein regulates cell motility, and that this interaction is disrupted in metastasizing cancer cells.

Investigators at Kobe University (Japan) worked with a cultured tumor cell line in studies that succeeding in identifying the link between the membrane-bending protein FBP17 (formin-binding protein-17) and the degree of tension found at a cell's leading edge formation.

The investigators reported in the May 4, 2015, online edition of the journal Nature Cell Biology that FBP17, an activator of WASP (Wiskott–Aldrich Syndrome protein)/N-WASP-dependent actin nucleation, was a plasma membrane tension sensor involved in leading edge formation. More...
In migrating cells, FBP17 localized to short membrane invaginations at the leading edge, while diminishing from the cell rear in response to plasma membrane tension increase. Conversely, following reduced plasma membrane tension, FBP17 dots randomly distributed throughout the cell, correlating with loss of polarized actin assembly on plasma membrane tension reduction.

In vitro experiments showed that FBP17 membrane-bending activity depended on liposomal membrane tension. Thus, FBP17 was the local activator of actin polymerization that was inhibited by plasma membrane tension in the feedback loop that regulated cell migration. The disruption of cell motility-regulating mechanisms has been cited as a key factor in cancer cell metastasis.

Senior author Dr. Toshiki Itoh, professor of biomedical science at Kobe University, said, "We are promoting research from a less studied perspective to identify new approaches to cancer treatment."

Related Links:

Kobe University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Hematology Consumables
Bioblood Devices
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.